Retatrutide is one of the newest triple agonist peptides being investigated for obesity and metabolic disorders. Early clinical trials have shown impressive reductions in body weight.
The molecule activates GLP-1, GIP and glucagon receptors simultaneously, making it different from older GLP-1 medications.
Why Researchers Are Excited
Clinical trials suggest participants experienced greater average weight reduction than previous GLP-1 therapies.
Researchers are continuing long-term studies to understand durability and safety.
Besides weight reduction, researchers observed improvements in several metabolic markers including blood glucose and waist circumference.
How It Works
Retatrutide works through three hormone pathways.
Potential benefits include:
Reduced appetite
Improved glucose regulation
Increased energy expenditure
Better fat metabolism
Dosage
Clinical trials gradually increased dosage over several weeks.
This helps reduce gastrointestinal side effects.
Side Effects
Most commonly reported effects include:
nausea
vomiting
diarrhea
constipation
Symptoms often improve as treatment continues.
Related Articles
FAQ
Is Retatrutide approved?
Approval depends on country and regulatory authority.
Is it stronger than Tirzepatide?
Early research suggests greater weight loss, although studies continue.
Can beginners use it?
Only under qualified medical supervision.
Sources
New England Journal of Medicine
ClinicalTrials.gov
Eli Lilly Research Publications